Ongoing Phase 2b Study in Parkinson’s Disease

A Multicenter, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson’s Disease Related Constipation (KARMET).

The study has been extended and is currently open for enrollment. The study was conducted at multiple US sites and 95 patients were enrolled over a 6-month period. Escalating doses were administered to 72 patients and titrated to a clinically efficacious or maximum dose, followed by a withdrawal period. An additional 80 patients will be enrolled in this study.  Participating sites include Albany, Hershey, Sarasota, Boca Raton,  Pasadena, Port Charlotte, Washington, D.C. and others. We would like to thank everyone involved for their support on this important trial.

For further information, please go to ClinicalTrials.gov or contact us at KARMETinfo@enterininc.com.